Mind Medicine (MindMed) (NASDAQ:MNMD) Rating Reiterated by HC Wainwright

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $75.00 price objective on the stock. HC Wainwright also issued estimates for Mind Medicine (MindMed)’s FY2027 earnings at $0.18 EPS.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada assumed coverage on shares of Mind Medicine (MindMed) in a research report on Wednesday, November 16th. They issued an “outperform” rating for the company. Maxim Group dropped their price objective on shares of Mind Medicine (MindMed) from $22.50 to $8.00 in a research report on Monday, November 14th. UBS Group assumed coverage on shares of Mind Medicine (MindMed) in a research report on Thursday, December 15th. They issued a “buy” rating and a $21.00 price objective for the company. EF Hutton Acquisition Co. I initiated coverage on shares of Mind Medicine (MindMed) in a research report on Friday, December 16th. They issued a “buy” rating and a $21.00 price objective for the company. Finally, Roth Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, December 9th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Mind Medicine (MindMed) presently has a consensus rating of “Buy” and a consensus price target of $33.13.

Mind Medicine (MindMed) Trading Up 7.3 %

NASDAQ:MNMD opened at $3.54 on Thursday. Mind Medicine has a 1 year low of $2.12 and a 1 year high of $22.20. The firm has a 50 day moving average of $2.74 and a 200-day moving average of $5.84. The stock has a market capitalization of $133.00 million, a P/E ratio of -1.50 and a beta of 1.63.

Mind Medicine (MindMed) (NASDAQ:MNMDGet Rating) last posted its earnings results on Thursday, November 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. As a group, analysts forecast that Mind Medicine will post -2.33 EPS for the current fiscal year.

Institutional Trading of Mind Medicine (MindMed)

A number of institutional investors have recently bought and sold shares of MNMD. LMR Partners LLP acquired a new position in shares of Mind Medicine (MindMed) in the 3rd quarter valued at $36,000. Exchange Traded Concepts LLC grew its holdings in shares of Mind Medicine (MindMed) by 235.1% in the 4th quarter. Exchange Traded Concepts LLC now owns 14,955 shares of the company’s stock valued at $33,000 after buying an additional 10,492 shares during the period. Virtu Financial LLC acquired a new position in shares of Mind Medicine (MindMed) in the 1st quarter valued at $29,000. Quantum Private Wealth LLC acquired a new position in shares of Mind Medicine (MindMed) in the 2nd quarter valued at $28,000. Finally, HighTower Advisors LLC grew its holdings in shares of Mind Medicine (MindMed) by 77.2% in the 1st quarter. HighTower Advisors LLC now owns 104,975 shares of the company’s stock valued at $119,000 after buying an additional 45,747 shares during the period. Institutional investors and hedge funds own 20.44% of the company’s stock.

About Mind Medicine (MindMed)

(Get Rating)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Further Reading

Analyst Recommendations for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.